Overview of Su-MAG

Property	Description
Active Ingredients	Magnesium Sulfate, Sulfacetamide Sodium, Urea
Form	Ointment or Cream
Pharmacological Class	Topical Antibacterial and Keratolytic Combination Agent
Route of Administration	Topical, External use only
Origin	Synthetic Combination Product

What Type of Medicine is Su-MAG? (Identity and Classification)

Su-MAG is defined as a multi-component, proprietary topical dermatological preparation that belongs to the class of Topical Antibacterial and Keratolytic Combination Agents. It is categorized as a synthetic combination product, designed to deliver the combined effects of multiple active substances to address minor skin surface issues. This formulation, typically produced as an ointment or cream, is strictly intended for topical administration and is designated for external use only. This unique fixed-dose combination targets areas where a dual action of surface cleansing and skin softening is necessary.

Active Ingredients and Composition of Su-MAG (Form and Composition)

The medicinal profile of Su-MAG is determined by its three principal active ingredients: Magnesium Sulfate, Sulfacetamide Sodium, and Urea. These are compounded into a stable Emulsion Base, often including ingredients like Glycerin to enhance the product’s humectant properties. The Sulfacetamide Sodium component is a sulfonamide-class antibacterial agent, clinically recognized for its ability to inhibit bacterial proliferation on the skin. Furthermore, Urea is a well-established keratolytic agent, supporting the dissolution and softening of hardened skin layers. Magnesium Sulfate contributes a known osmotic action that helps manage local skin irritation, creating a comprehensive topical formulation.

What is the General Purpose of Su-MAG? (Mechanism and General Benefit)

The general purpose of Su-MAG is to support the skin's natural recovery process through a collective multi-action mechanism. This preparation generally helps to relieve discomfort and maintain the integrity of compromised skin by simultaneously promoting the softening and renewal of rough patches and ensuring targeted cleansing of the area. A typical, neutral use scenario involves applying the preparation to manage minor skin irritations or hyperkeratotic surface lesions where both dryness and a need for surface protection are present. The combination is specifically designed to create a favorable microenvironment for the healing of minor external irritations.

Regulatory References

Sulfacetamide Monograph - DailyMed/NIH

What side effects are possible with Su-MAG?

Possible Side Effects and Safety Information

The safety profile of Su-MAG, a topical combination preparation, is characterized by localized dermatological reactions and the potential for rare, but serious systemic effects associated with the sulfonamide component, Sulfacetamide Sodium. Adverse reactions are classified based on frequency as documented in official regulatory labeling.

Adverse Reactions and Classification

Category	Documented Effects
Common / Expected	Local irritation, burning, stinging sensation, erythema (redness), and drying of the skin. These are often transient and associated with initial application.
Uncommon	Reports of contact dermatitis and localized hypersensitivity reactions.
Rare / Serious	Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Fatal Agranulocytosis, and Acute Hemolytic Anemia. These are risks linked to systemic absorption of sulfonamides.

Population-Specific and Use Restrictions

Official labeling defines specific restrictions for use. Su-MAG is contraindicated in individuals with a known hypersensitivity to any component or to other sulfonamide-class medicines. It is also contraindicated in patients with severe renal impairment (kidney disease) due to the risk of systemic sulfonamide toxicity. The safety and effectiveness of the preparation have not been established in children under 12 years of age. Systemic absorption may be greater if the product is applied to large, infected, abraded, or denuded areas of the skin, which may increase the risk of rare, serious effects. Caution is advised for local irritation or sensitization during long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on authoritative government regulatory documents for Magnesium Sulfate, the active substance implied by Su-MAG.

Overdose with Magnesium Sulfate is primarily associated with hypermagnesemia, which can lead to serious physiological changes.

Documented Overdose Manifestations

Clinical signs of overdose, which can be dose-dependent, include:

Neuromuscular: Loss or depression of deep tendon reflexes (such as the patellar reflex), muscle weakness, and flaccid paralysis.
Cardiovascular: A sharp drop in blood pressure (hypotension), flushing, and sweating.
Central/Respiratory: Central Nervous System (CNS) depression, lethargy, somnolence, and decreased respiratory rate.

Severe and Life-Threatening Outcomes

Severe hypermagnesemia carries the risk of life-threatening events, including respiratory paralysis, circulatory collapse, and cardiac arrest.

Required Emergency Actions

Regulatory instructions specify that the infusion must be immediately discontinued if signs of toxicity are present. An injectable calcium salt (such as calcium gluconate) must be immediately available and administered to counteract the effects of magnesium toxicity. Artificial respiration and supportive ventilation may be required.

When Immediate Medical Help is Required: The disappearance of the patellar reflex is a critical clinical sign indicating the onset of magnesium intoxication, which mandates immediate action and medical evaluation.

Therapeutic Uses of Su-MAG

What Su-MAG Treats: Main Uses and Benefits

Su-MAG is applied in contexts where localized skin support is needed to manage a cluster of symptoms, focusing on physical texture, scaling, and surface hygiene. It is relevant across domains where short-term symptomatic assistance is appropriate to help ease the overall symptom burden and generally contributes to improved comfort. This combination is relevant for managing symptoms associated with acne vulgaris and seborrheic dermatitis.

This product is commonly used across conditions presenting with epidermal thickening, roughness, and excessive scaling, and it provides relief for superficial blemishes and minor irritations, including those from small cuts, scrapes, and abrasions. It is applied in addressing symptom clusters related to surface contamination and the appearance of small papules or pustules, such as those seen in mild acne and superficial folliculitis. The formulation helps patients cope more steadily with difficult episodes by softening the hardened surface layers and supporting the gentle renewal of the skin's texture.

Quick Fact: Relief for Hyperkeratosis Su-MAG is used to manage symptoms where skin presents with excessive thickening and roughness, supporting surface hygiene and texture improvement.

Regulatory References

National Library of Medicine's DailyMed service

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Su-MAG — Official Regulatory Information

The eligibility profile for Su-MAG (Magnesium Sulfate, Sulfacetamide Sodium, Urea) is defined by strict regulatory criteria documented by government authorities.

Eligibility Scope	Official Regulatory Status
Populations Contraindicated	Persons with known or suspected hypersensitivity to any product ingredient or to sulfa drugs (sulfonamides). Patients with kidney disease or renal dysfunction.
Age-Related Eligibility	Established use is for Adults and Adolescents (≥12 years). Safety and effectiveness in children under 12 years have not been established.
Pregnancy and Lactation	Use in pregnancy is restricted (Category C) and should occur only if clearly needed. Caution is required for use by nursing women.
Conditional Use	Use requires caution when applying to large, infected, abraded, or denuded areas of the skin due to the risk of increased systemic absorption. Caution is also required for patients with comorbidities like Porphyria or Liver Disease.

Official regulatory documents strictly prohibit use in patients with a sulfa-drug allergy or renal disease. Established use is limited to patients 12 years and older, with specific restrictions applying to compromised skin and reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Su-MAG, based on the potential systemic effects of its Sulfacetamide Sodium component, as stated in government regulatory labeling.

Documented Drug-Drug Interactions

Interacting Product Category	Official Interaction Outcome
Oral Anticoagulants (e.g., Warfarin)	Co-administration may potentiate the anticoagulant effect, increasing the risk of bleeding. This is an exposure modification concern based on systemic sulfonamide risks.
Phenytoin (Anticonvulsant)	Co-administration may inhibit metabolism, leading to increased plasma concentrations (increased exposure) of Phenytoin.
Hypoglycemic Agents (Sulfonylureas)	May increase the glucose-lowering effect (pharmacodynamic potentiation), based on systemic sulfonamide risk.
Diuretics and Carbonic Anhydrase Inhibitors	Co-administration is associated with a heightened risk of specific hypersensitivity reactions due to chemical structural similarity.

Other Interaction Restrictions

Chemical Incompatibility: The product is not to be co-administered with silver preparations due to documented chemical incompatibility with sulfacetamide components. Furthermore, the antibacterial effectiveness of Sulfacetamide may be antagonized by products containing P-Aminobenzoic Acid (PABA) or its derivatives. No formal restrictions or documented interaction patterns exist in regulatory labels for co-use with food, alcohol, or herbal supplements for this topical combination.

Mechanism of Action

How Su-MAG Works

The action of Su-MAG is defined by the coordinated pharmacodynamic mechanisms of its three components, engaging distinct biological targets, resulting in localized physiological changes.

Modulation of Microbial Metabolic Pathways

The Sulfacetamide Sodium component initiates a bacteriostatic outcome by targeting the Dihydropteroate Synthase (DHPS) enzyme in the microbial metabolic pathway . This active ingredient functions as a competitive inhibitor against the enzyme's natural substrate, PABA, thereby blocking the synthesis of essential folic acid and limiting the proliferation of surface bacteria.

Structurally Remodeling the Keratin Layer

The Urea component acts as a keratolytic agent, physically interacting with the structural proteins of the stratum corneum. This mechanism involves the chemical disruption of hydrogen bonds that maintain the rigidity of keratin, leading to the softening, dissolution, and normalization of thickened skin layers. This structural remodeling process influences tissue turnover and hydration status.

Osmotic Modulation and Mechanistic Synergy

Magnesium Sulfate creates a hyperosmotic gradient on the skin surface, a physical mechanism that draws out interstitial fluid, which modulates local tissue fluid dynamics. The keratolytic action of Urea facilitates mechanistic synergy by softening the outer skin layer, enhancing the local penetration and availability of Sulfacetamide Sodium to its microbial targets.

Dosage and Administration Information

The use of Su-MAG is defined by a structured, topical administration protocol for its active components, Sulfacetamide Sodium and Urea. The medicine is designated for external use only on the skin surface.

Administration Scope

Route of administration: Topical (for external use on the skin only).

Dosing schedule: Apply a thin film/layer of the preparation to the entire affected area. Standard frequency is typically once or twice daily, though application may range up to three times per day, depending on the specific product formulation.

Preparation requirements (if applicable): The skin must be cleansed thoroughly before each application. For liquid or suspension forms, the container must be shaken well prior to use.

Age-group administration rules: The safety and effectiveness of the product in children under the age of 12 years have not been established.

Special procedural conditions: Application must avoid contact with eyes, eyelids, lips, and mucous membranes. If excessive dryness occurs, the frequency of application or duration of contact (for cleansers) should be reduced, such as by using the product less often.

Resulting Procedural Structure

The resulting procedural structure is defined by the following sequence:

Cleansing the affected skin area thoroughly.
Shaking the container (if applicable).
Applying a thin film of the product to the affected area.
Massaging the product gently into the skin.
Rinsing the product off thoroughly (for wash/cleanser forms).

Connection to the overall use protocol: The instructions establish a structured, topical use protocol that specifies the administration route, the required frequency, and the precise application technique. This framework ensures that the product is applied in a defined manner and dictates a defined adjustment logic if local drying occurs.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Su-MAG

Evidence for Use in Acne Vulgaris

The research base for acne vulgaris primarily involves Randomized Controlled Trials (RCTs) and open-label studies that were conducted to evaluate combination products containing the sulfonamide component present in Su-MAG. These studies generally focused on populations of adults and adolescents (16 years and older) with mild to moderate acne. Researchers focused on measuring outcomes related to inflammatory lesion counts and the overall change in total lesion counts.

The studies generally report the outcomes measured by researchers over typical observation periods of 8 to 12 weeks. Some trials documented shifts in investigator-assigned severity scores observed in association with sulfonamide-based topical formulations. Comparative evidence is lacking for the specific three-ingredient combination. The majority of this evidence is focused on a two-component formulation (sulfacetamide/sulfur) that is similar to, but not identical to, the complete three-component Su-MAG product.

Evidence for Use in Seborrheic Dermatitis

For conditions characterized by fluctuating or episodic manifestations like seborrheic dermatitis, the evidence base often consists of Observational Studies and case series. These studies monitored outcomes linked to inflammatory or irritative states, such as visible scaling, flaking, and patient-reported discomfort like itching (pruritus). The findings describe patterns observed in the studies where physician assessments documented overall changes in the signs of the condition, typically over short-term intervals of around 8 weeks.

Evidence for the specific three-component Su-MAG formulation for seborrheic dermatitis does not include a substantial number of large-scale, blinded, comparative RCTs. Research provides limited insight into the maintenance of measured outcomes after the study observation period.

Unanswered Questions and Research Gaps

A primary research limitation is that many high-level findings are drawn from studies of similar but not identical two-component formulations. Furthermore, there is limited information on the precise way the three ingredients—Sulfacetamide Sodium, Urea, and Magnesium Sulfate—may interact to produce the final measured outcomes. Long-term data are not fully established beyond the first few months of use, and data for certain groups remain insufficient, particularly for very young children or older adults.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Su-MAG (FAQ)

Q: How quickly does Su-MAG start to affect my condition?

A: Official studies do not typically report an immediate onset time in days or hours for this topical product. Instead, clinical effectiveness is generally assessed based on changes observed over a period of consistent use. Research indicates that outcomes are typically evaluated after several weeks, commonly 8 to 12 weeks of therapy.

Q: How long can a person expect to take Su-MAG?

A: Official long-term data for continuous use of this product are limited. The research evidence that has been reported generally covers outcomes measured over short-term periods. This means the majority of available data is based on usage up to approximately 8 to 12 weeks of continuous therapy.

Q: Are the side effects of Su-MAG permanent?

A: According to official product information, common side effects such as local irritation, stinging, and redness are often described as transient (temporary). These effects may lessen as the skin adjusts to the medication.

Q: Can older adults use Su-MAG, and are there special considerations?

A: Data on the use and specific effects of this topical product in older adults are limited. Regulatory documents indicate that a research gap exists concerning its full safety and effectiveness in this particular population.

Q: How do I know if Su-MAG is actually working for me?

A: In clinical studies, the product is measured by observing a reduction in symptoms related to the condition being managed. This includes a decrease in inflammatory lesions, visible scaling, or flaking.

Q: What does 'contraindicated' mean in relation to Su-MAG?

A: Contraindicated is a formal term used in regulatory documents to signify a condition where the product should officially not be used. This is because the potential risks are known to outweigh the benefits, such as having a known severe sulfa drug allergy or severe kidney disease.

Q: What if I have allergies? Should I be concerned about taking Su-MAG?

A: The main safety concern documented in official labeling is a known or suspected hypersensitivity (allergy) to sulfa drugs (sulfonamides) or any of the product's components. Specific allergies, such as those to sulfa drugs, are officially documented reasons for the product to be contraindicated.

Q: What are the components, besides the main drug, in Su-MAG?

A: Regulatory documents confirm that, in addition to the three active ingredients, a product contains various inactive ingredients (excipients). The full list of these components varies based on the specific product form and manufacturer, and this information is detailed in the official product labeling.

Q: What should I do if I miss a dose of Su-MAG?

A: Official administration documents describe the protocol if a dose is missed. This protocol generally states to apply the product as soon as remembered; however, if it is nearly time for the next dose, the instruction is to skip the missed dose. Regulatory labeling further states that extra or double the amount should not be used to catch up.

Q: Does taking Su-MAG cause weight gain or weight loss?

A: Weight gain or weight loss is not reported as a common or rare side effect in the official adverse reaction data for this topical product.

Q: Is it common to feel tired when first starting Su-MAG?

A: Mild tiredness is not a common or expected side effect for this topical preparation. Regulatory documents caution that unusual weakness or tiredness can be a symptom associated with rare but serious systemic reactions like blood disorders, and is a symptom that should be discussed with a healthcare provider.

Q: Do the side effects of Su-MAG get worse over time?

A: Official regulatory documents caution that potential local irritation or sensitization may occur when using the product for long periods. The labeling indicates that use should be discontinued if signs of hypersensitivity develop.

Q: Does Su-MAG interact with birth control pills?

A: Regulatory documents indicate a potential drug-drug interaction. The systemic absorption of sulfonamides may potentially decrease the effectiveness of certain hormonal contraceptives. This potential interaction is generally considered a topic for discussion between the patient and a healthcare provider.

Q: Does Su-MAG affect my ability to drive or operate machinery?

A: Official regulatory labels do not contain a specific warning against driving or operating machinery for this topical product. This is consistent with its topical route of administration and lack of common effects on the central nervous system.

Q: What kind of monitoring or tests are needed while taking Su-MAG?

A: For patients using the product on large, infected, or severely compromised areas of skin, or if signs of systemic effects occur, official sources state that appropriate observations and laboratory determinations (such as blood tests) may be performed by healthcare providers.

Q: Can men or women with fertility concerns take Su-MAG?

A: Official regulatory documents state that long-term studies to evaluate fertility or reproductive capacity have not been performed for this topical product.

Q: Does Su-MAG affect mood or cause any psychological changes?

A: Regulatory documents list mental depression as an adverse reaction whose incidence is not known. This is typically linked to the rare systemic effects that can occur from the sulfonamide component.

Q: What should I do if a side effect seems unusual or severe?

A: Regulatory labeling states that the use of the product should be discontinued immediately if signs of hypersensitivity, a skin rash, or other unusual reactions occur. This includes serious systemic signs such as fever, arthritis, or sores in the mouth.

Q: Is Su-MAG a controlled substance?

A: The product is classified as an Rx only (prescription-only) medication. It is not listed as a scheduled controlled substance by regulatory authorities.

Q: Is Su-MAG known to cause liver damage?

A: Severe liver damage (fulminant hepatic necrosis) is an extremely rare but serious adverse reaction that has been reported, linked to the systemic absorption of the sulfonamide component. Official documents note that signs such as jaundice (yellowing skin) may be associated with this rare reaction.

Q: How long does Su-MAG stay in your system after stopping treatment?

A: Regulatory labels indicate that no clinical data are available on the degree and rate of systemic absorption of the product when applied to the skin. Therefore, the exact time the drug remains in the system is not established.

Q: Does Su-MAG have a 'black box warning' in the US, and what does that mean?

A: The product is not typically required to carry a Black Box Warning (Boxed Warning) in its labeling. However, its official regulatory label includes prominent Warnings about the rare but serious risks of systemic reactions such as Stevens-Johnson syndrome, blood disorders, and severe liver problems.

How should Su-MAG be stored and disposed of?

How to Store and Dispose of Su-MAG

Storage and disposal of Su-MAG (a topical Sulfacetamide Sodium/Urea product) must strictly follow official regulatory guidelines to maintain its stability.

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C.
Protection	Must be protected from freezing and excessive heat.
Container	Keep bottle tightly closed when not in use.

Discoloration: Official labeling notes that a slight darkening or discoloration may occur upon storage, but this does not compromise the product’s efficacy or safety.

Disposal and Safety

All medications must be kept away from children and pets. Unused or expired Su-MAG should be disposed of properly. Do not pour the product down a drain or flush it unless specifically instructed by official guidance. The recommended disposal method is to mix the product with an undesirable substance, seal it, and discard it in household trash.

Su-MAG